BetterLife Pharma Inc. (FRA:NPAU)
| Market Cap | 93.82M +1,295.3% |
| Revenue (ttm) | n/a |
| Net Income | -2.16M |
| EPS | -0.01 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 7,000 |
| Open | 0.1460 |
| Previous Close | 0.1460 |
| Day's Range | 0.1460 - 0.1660 |
| 52-Week Range | 0.0175 - 0.2660 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Dec 30, 2026 |
About BetterLife Pharma
BetterLife Pharma Inc., a biotechnology company, engages in the development of psychedelic-derived compounds. It focuses on developing and commercializing BETR-001, a non-hallucinogenic and non-controlled LSD derivative to treat neuro-psychiatric and neurological disorders. Its products also comprise MM-001, a topical cream for local intravaginal use to treat HPV-induced cervical intraepithelial neoplasia; and MM-003, a patent pending proprietary interferon alpha-2b inhalation formulation. The company was formerly known as Pivot Pharmaceuticals... [Read more]
News
BetterLife Pharma Appoints Professor Richard B. Lipton as Co-Chair of its Scientific Advisory Board
Director of the Montefiore Headache Center and past President of the American Headache Society joins Professor Peter Goadsby in leading the SAB for BETR-001 Vancouver, British Columbia--(Newsfile Corp...
BetterLife Pharma Appoints Sheila Leitzinger as Head of Clinical Operations
Clinical development veteran to lead execution of the first-in-human study of BETR-001 ahead of programs in chronic cluster headache and chronic migraine Vancouver, British Columbia--(Newsfile Corp. -...
BetterLife Pharma Establishes Scientific Advisory Board for Headache Program; Professor Peter Goadsby Appointed Co-Chair
Brain Prize co-recipient whose research identified CGRP as a central driver of migraine joins to guide development of BETR-001 in chronic cluster headache and chronic migraine Vancouver, British Colum...
BetterLife Pharma Addresses Notice of Civil Claim Filed by Steven Sangha
Vancouver, British Columbia--(Newsfile Corp. - October 9, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), today issued a statement regarding a No...
BetterLife Pharma Announces Rescheduling and Reclassification of Annual General Meeting to Annual General and Special Meeting
Vancouver, British Columbia--(Newsfile Corp. - September 29, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), an emerging biotechnology company de...
BetterLife Pharma Inc. Announces Closing of US$100 Million Public Offering of Common Shares and Pre-Funded Warrants
Vancouver, British Columbia--(Newsfile Corp. - September 17, 2026) - BetterLife Pharma Inc. (CSE: BETR) ("BetterLife" or the "Company"), a biotechnology company developing treatments for neurological ...
BetterLife Pharma Inc. Announces Filing of Final Prospectus for US$100 Million Public Offering of Common Shares and Pre-Funded Warrants
FINAL PROSPECTUS ACCESSIBLE ON SEDAR+ Vancouver, British Columbia--(Newsfile Corp. - September 11, 2026) - BetterLife Pharma Inc. (CSE: BETR) ("BetterLife" or the "Company"), a biotechnology company d...
BetterLife Pharma Appoints Charles Duncan as Director and Chair of the Audit Committee
Vancouver, British Columbia--(Newsfile Corp. - August 31, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), an emerging biotechnology company devel...
BetterLife Pharma Inc. Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants
Vancouver, British Columbia--(Newsfile Corp. - August 24, 2026) - BetterLife Pharma Inc. (CSE: BETR) ("BetterLife" or the "Company"), a biotechnology company developing treatments for neurological dis...
BetterLife Pharma Appoints Mahan Chehrenama, DO, as Chief Medical Officer
Vancouver, British Columbia--(Newsfile Corp. - August 19, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), a biotechnology company developing trea...
BetterLife Pharma Prioritizes BETR-001 to Lead in Migraine and Headache Disorders, Targeting a Clinically Validated, FDA-Precedented Serotonergic Mechanism
Fully non-hallucinogenic, oral, non-scheduled 5-HT2A neuroplastogen differentiates BETR-001 from every other 5-HT2A agonist program; depression and other psychiatric disorders retained as optional fut...
BetterLife Engages Nucro-Technics to Complete the last GLP Toxicology Study of BETR-001 Required by the FDA for IND and Phase 1
Vancouver, British Columbia--(Newsfile Corp. - July 6, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company") announces it has entered into an agreement ...
BetterLife Engages Syner-G to Oversee GMP Manufacturing of BETR-001 for IND and Phase 1
Vancouver, British Columbia--(Newsfile Corp. - June 25, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company") announces it has entered into an agreement...
BetterLife Pharma Secures CAD $2 Million in New Capital to Complete BETR-001 FDA IND Filing
Vancouver, British Columbia--(Newsfile Corp. - June 22, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company") today announced it has closed a CAD $2,000...
BetterLife Pharma to Participate in YAFO Capital Access Asia Partnering Forum During JPM Week in San Francisco
Vancouver, British Columbia--(Newsfile Corp. - January 6, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), an emerging biopharmaceutical company f...
BetterLife Pharma Highlights Advantages of BETR-001 -- a Potent Neuroplastogen
VANCOUVER, British Columbia – TheNewswire - December 4, 2025 - BetterLife Pharma Inc. (“BetterLife” or the “Compa ny”) ( CSE: BETR / OTCQB: BETRF / FRA: NPAU) , an emerging biotech company, focused o...
BetterLife Pharma Welcomes Daniel Carcillo as Corporate Advisor
VANCOUVER, British Columbia, November 25, 2025 – TheNewswire - BetterLife Pharma Inc. (“BetterLife” or the “Compa ny”) ( CSE: BETR / OTCQB: BETRF / FRA: NPAU) , an emerging biotech company, focused o...
USPTO Files ISSUE NOTIFICATION for BetterLife's BETR-001 Composition of Matter Patent
VANCOUVER, British Columbia, June 18, 2025 – TheNewswire - BetterLife Pharma Inc. (“BetterLife” or the “Compa ny”) ( CSE: BETR / OTCQB : BETRF / FRA: NPAU) , an emerging biotech company focused on th...
BetterLife provides update on neuroplastogenic activity of BETR-001
BetterLife (BETRF) Pharma recently presented a scientific update at Bloom Burton Conference on May 5, 2025 in Toronto, Canada. The emerging new paradigm in treating psychiatric and neurological disord...
BetterLife comments on CEO’s share position ownership
BetterLife (BETRF) Pharma is issuing the a press release in response to British Columbia Securities Commission’s May 21, 2025 news release. BetterLife announced on July 16, 2024, that it had…
BetterLife provides update of mechanism of action of BETR-001
BetterLife (BETRF) Pharma recently presented a scientific update at Bloom Burton Conference on May 5, 2025 in Toronto, Canada. BetterLife reported that its proprietary compound, BETR-001, is showing v...
BetterLife Pharma Provides Scientific Update of Mechanism of Action of BETR-001 in Treatment of Psychiatric Disorders
VANCOUVER, British Columbia, May 14, 2025 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB : BETRF / FRA: NPAU), an emerging biotech company focused on the...
BetterLife Announces Debt Settlements
VANCOUVER, British Columbia, May 06, 2025 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the ...
BetterLife appoints Andre Beaudry as corporate advisor
BetterLife (BETRF) Pharma has appointed Andre Beaudry as Corporate Advisor. Beaudry has led teams in Canada, China, England, India and the Philippines, and collaborated with industry, education, gover...
BetterLife Pharma Appoints Corporate Advisor
VANCOUVER, British Columbia, April 03, 2025 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB : BETRF / FRA: NPAU), an emerging biotech company, has announc...